Here was the last meaningful update from the company on MANF in 2018. So much science and IND preparation has been done since then.
MANF Therapeutics
MANF Therapeutics continues to amass a tremendous portfolio of intellectual
property covering the use of MANF in the treatment of a range of disorders.
While still in pre-clinical development, the next major step for this program
is the appointment of a Chief Medical Advisor who can help finalize the
selection of the initial indication for first-in-man studies with MANF, and
drive the program towards the clinic. There is significant reason to believe
that successful first-in-man studies with MANF could have a dramatic impact on
the rNPV of the MANF asset, as positive efficacy in one indication likely
increases the potential of a positive outcome in other, potentially larger,
indications. Amarantus has continued to work with key groups, including the
Snow Foundation focused on developing new treatments for Wolfram's Syndrome,
to advance the science underpinning MANF so that upon proper capitalization
this asset can be swiftly moved to complete IND-enabling studies in
preparation for first-in-man. Amarantus continues to believe that MANF is
potentially the most valuable asset in the Amarantus portfolio and the Company
will continue to invest in the IP underpinning MANF until such time that MANF
Therapeutics can independently finance its development. With potential
disease-modifying applications in Glaucoma, Parkinson's disease, Alzheimer's
disease, myocardial infarction and diabetes, human proof of concept with MANF
in an orphan indication would significantly drive the rNPV for MANF by
establishing a reasonable risk adjusted discount to its value in the event of
success in these larger indications.
